{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:20:25Z","timestamp":1792441225943,"version":"4.5.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Despite the wide use of statins and other LDL-cholesterol (LDL-C)-lowering therapies, atherosclerotic cardiovascular disease remains an important cause of mortality and morbidity. Here, we discuss efficacy, side effects and convenience of current and future therapies inhibiting proprotein convertase subtilisin\/kexin type 9 (PCSK9).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Clinical trials with mAbs administered every 2\u20134 weeks and small interfering RNAs given two to four times per year have consistently demonstrated substantial LDL-C-lowering (40\u201360%) and improved outcome when added to existing lipid-lowering therapies. Pleiotropic effects of PCSK9 inhibition are somewhat different from those observed with statin treatment as evidenced by reduced levels of triglycerides and lipoprotein(a) with no apparent effect on inflammatory markers in patients treated with PCSK9 inhibitors. Treatment with mAb and small interfering RNA are associated with a high-cost, however, small molecules and vaccines may improve cost and convenience if development of these are successful.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>PCSK9 inhibitors are currently considered to be an add-on therapy and whether these drugs will be used as stand-alone and\/or as a first choice is dependent on clinical readouts from ongoing and future trials, real-world evidence, convenience and treatment costs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000718","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T20:44:38Z","timestamp":1602794678000},"page":"340-346","source":"Crossref","is-referenced-by-count":11,"title":["Proprotein convertase subtilisin\/kexin type 9 inhibition as the next statin?"],"prefix":"10.1097","volume":"31","author":[{"given":"G\u00fcnaj","family":"Rakipovski","sequence":"first","affiliation":[{"name":"Novo Nordisk A\/S, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, Copenhagen, Denmark"},{"name":"Department of Vascular Medicine, Amsterdam UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nyberg","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,10,14]]},"reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ni.2001","article-title":"The immune system in atherosclerosis","volume":"12","author":"Hansson","year":"2011","journal-title":"Nat Immunol"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"e29849","DOI":"10.1371\/journal.pone.0029849","article-title":"Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy","volume":"7","author":"Emberson","year":"2012","journal-title":"PLoS One"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/jamacardio.2018.4948","article-title":"Statins work, but only in people who take them","volume":"4","author":"Navar","year":"2019","journal-title":"JAMA Cardiol"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11886-015-0665-x","article-title":"New approaches in detection and treatment of familial hypercholesterolemia","volume":"17","author":"Hartgers","year":"2015","journal-title":"Curr Cardiol Rep"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","article-title":"PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells","volume":"25","author":"Lagace","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","article-title":"Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial","volume":"73","author":"Szarek","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","article-title":"Molecular mechanisms and biological functions of siRNA","volume":"13","author":"Dana","year":"2017","journal-title":"Int J Biomed Sci"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1194\/jlr.M092486","article-title":"Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia","volume":"60","author":"Sokolov","year":"2019","journal-title":"J Lipid Res"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur Heart J"},{"key":"R19-20230917","first-page":"cvaa077","article-title":"Effect of inclisiran, the siRNA against PCSK9, on platelets, immune cells and immunological biomarkers \u2013 a prespecified analysis from ORION-1","author":"Landmesser","year":"2020","journal-title":"Cardiovasc Res"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"Swerdlow","year":"2015","journal-title":"Lancet"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41574-018-0110-5","article-title":"Inhibiting PCSK9 \u2013 biology beyond LDL control","volume":"15","author":"Stoekenbroek","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nrendo.2017.145","article-title":"Diabetes: anti-PCSK9 antibodies \u2013 beneficial or inducers of diabetes?","volume":"13","author":"Verbeek","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11789-019-00095-3","article-title":"Lipoprotein(a) and mortality \u2013 a high risk relationship","volume":"14","author":"Klingel","year":"2019","journal-title":"Clin Res Cardiol Suppl"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"(Suppl 1)","key":"R28-20230917","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/dom.13691","article-title":"The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes","volume":"21","author":"Gonna","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s00125-019-4856-7","article-title":"Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study","volume":"62","author":"Rosenson","year":"2019","journal-title":"Diabetologia"},{"key":"R30-20230917","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"R31-20230917","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","article-title":"Inflammatory and cholesterol risk in the FOURIER trial","volume":"138","author":"Bohula","year":"2018","journal-title":"Circulation"},{"key":"R32-20230917","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/CIRCULATIONAHA.118.038840","article-title":"Effect of alirocumab on mortality after acute coronary syndromes","volume":"140","author":"Steg","year":"2019","journal-title":"Circulation"},{"key":"R33-20230917","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2019.07.015","article-title":"PCSK9 inhibition and inflammation: a narrative review","volume":"288","author":"Ruscica","year":"2019","journal-title":"Atherosclerosis"},{"key":"R34-20230917","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1016\/j.jcmg.2019.06.022","article-title":"PCSK9 antibody alirocumab attenuates arterial wall inflammation without changes in circulating inflammatory markers","volume":"12","author":"Hoogeveen","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1194\/jlr.RA119000419","article-title":"Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice","volume":"61","author":"Pouwer","year":"2020","journal-title":"J Lipid Res"},{"key":"R36-20230917","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"R37-20230917","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"R39-20230917","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacl.2020.01.001","article-title":"Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial","volume":"14","author":"Moriarty","year":"2020","journal-title":"J Clin Lipidol"},{"key":"R40-20230917","doi-asserted-by":"crossref","first-page":"e0191895","DOI":"10.1371\/journal.pone.0191895","article-title":"Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin\/kexin type 9 (PCSK9) epitope in mice","volume":"13","author":"Kawakami","year":"2018","journal-title":"PLoS One"},{"key":"R41-20230917","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE\u22173Leiden.CETP mice","volume":"38","author":"Landlinger","year":"2017","journal-title":"Eur Heart J"},{"key":"R42-20230917","doi-asserted-by":"crossref","first-page":"e0225780","DOI":"10.1371\/journal.pone.0225780","article-title":"Fragment-based design of small molecule PCSK9 inhibitors using simulated annealing of chemical potential simulations","volume":"14","author":"Guarnieri","year":"2019","journal-title":"PLoS One"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000718","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T07:08:40Z","timestamp":1694934520000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,14]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000718","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,14]]}}}